BridgeMD
New treatment option for Epilepsy
Official title AI-Based Mobile Intervention on Medication Non-Adherence and Transition
ClinicalTrials.gov ID: NCT07445074
What this study is testing
- What it's testing
- This study aims to examine whether the AI-personalized version of the Medilepsy® app is more effective than the non-AI (standard version without AI personalization) can improve key outcomes, such as medical adherence and transition readiness, among underserved adolescents and young adults with epilepsy, ages 14-24, in Florida, USA. Outcomes are organized into primary (effectiveness), secondary (usability), and exploratory (language experience) endpoints.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 14 to 24
You may be able to join if
- Diagnosed with epilepsy
- Currently prescribed anti-seizure medicine (ASMs)
- Identified as part of an underserved population, defined as meeting at least one of the following: member of a racial or ethnic group historically...
- Are between 14-17 years old and able to provide assent, with a parent or LAR present to receive app notifications throughout the study
- Are between 18-24 years old and able to provide informed consent
You likely can't join if
- They do not own a mobile device with internet access.
- They have a history of severe intellectual disability.
- They are unable to operate a mobile device (keyboard or touchscreen).
- Reside in an in-patient setting.
- Adults unable to consent.
- Pregnant women (excluded because pregnancy is not relevant to the study focus).
See the full eligibility criteria
- Diagnosed with epilepsy
- Currently prescribed anti-seizure medicine (ASMs)
- Identified as part of an underserved population, defined as meeting at least one of the following: member of a racial or ethnic group historically underrepresented in research or healthcare or low-income status (e.g...
- Are between 14-17 years old and able to provide assent, with a parent or LAR present to receive app notifications throughout the study
- Are between 18-24 years old and able to provide informed consent
- Able to read, speak, and write in English
- Resides in Florida
- Receive outpatient medical services
- They do not own a mobile device with internet access.
- They have a history of severe intellectual disability.
- They are unable to operate a mobile device (keyboard or touchscreen).
- Reside in an in-patient setting.
- Adults unable to consent.
- Pregnant women (excluded because pregnancy is not relevant to the study focus).
- Prisoners.
The study team makes the final eligibility decision.
Where it's taking place
- Orlando, Florida, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 14 years to 24 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Orlando, Florida, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.